Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2461-2480 of 3,900 trials

Vibegron for Children with Neurogenic Detrusor Overactivity

We are studying the safety and effectiveness of vibegron in children aged 2 to under 18 with neurogenic detrusor overactivity who use clean intermittent catheterization. This trial aims to understand how well the medication works and how it is processed in young patients.

Neurogenic Bladder1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsUrology

Ovarian Stimulation: Follitropin Delta and Dydrogesterone

We are studying a new ovarian stimulation method for egg donors to see if it produces similar results to traditional approaches. This research may help improve fertility treatments in the future.

Healthy Oocyte Donors1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Early Alzheimer's Disease: NIO752 Study

We are investigating a new medication for people with early Alzheimer's disease to assess its safety and how it works in the body. This study aims to gather important information about the treatment's effects.

Alzheimer's Disease>2 yearsSafety phase (I)Neurology

Advanced Cancers: FS222 Antibody Treatment

We are evaluating a new antibody medication for individuals with advanced cancers to see if it is safe and effective. This study aims to understand how well FS222 works in treating these conditions.

Advanced Cancer>2 yearsSafety phase (I)Oncology

Acute Myeloid Leukemia: Midostaurin and Gemtuzumab Ozogamicin

We are studying a new combination treatment for patients with acute myeloid leukemia to see if it is safe and effective alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Osteoarthritis of the Knee: SAR446959 Study

We are investigating a new treatment to see if it is safe and well-tolerated by people with knee osteoarthritis. This study aims to gather important information about its effects on participants.

Osteoarthritis1-2 yearsSafety phase (I)Internal MedicineOrthopedics and Traumatology

Craniotomy Pain Management: S-Ketamine Study

We are investigating whether adding s-ketamine to standard pain relief helps reduce opioid use and improve pain control after craniotomy in patients with drug-resistant epilepsy.

Post-Craniotomy Headache6-12 monthsMonitoring phase (IV)Standard MedicinesNeurologyOtolaryngologyPsychiatry

Breast Cancer: Genomics Guided Therapy Study

We are exploring whether a personalized treatment approach after surgery can improve outcomes for patients with early high-risk breast cancer. This study will assess survival rates and the safety of the new therapy.

Early Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Retinoblastoma: New Treatment Strategies

We are studying the effectiveness of a new chemotherapy method and other conservative treatments for children with retinoblastoma. Our goal is to see how well these treatments control the disease and support visual health.

Retinoblastoma Treatment>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Early Stage Arthritis: Baricitinib Study

We are studying the effects of baricitinib on joint inflammation in people with early stage arthritis. The trial will also look at safety and potential indicators of disease progression.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Standard MedicinesRheumatology

Colorectal Cancer: New Treatment with 5-Fluorouracil, Panitumumab, and Sotorasib

We are studying a combination of medications for patients with advanced colorectal cancer who cannot receive standard chemotherapy. The goal is to see if this treatment helps control the disease and improves quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Cervical Cancer: Relatlimab and Nivolumab Study

We are exploring whether combining Relatlimab with Nivolumab is more effective than Nivolumab alone for treating locally advanced cervical cancer. This study aims to find better treatment options for patients.

Cervical Cancer>2 yearsEfficacy phase (II)Oncology

Advanced Cancer: BI 765063 and BI 770371 Study

We are studying how two new drugs are taken up in tumors of people with different types of advanced cancer who are also receiving Ezabenlimab. This research may help improve future cancer treatments.

Non-Small Cell Lung CancerMelanomaHead and Neck Squamous Cell CarcinomaSafety phase (I)Oncology

Sepsis Treatment: Aminoglycoside Antibiotics and Isolation

We are studying the effects of combining aminoglycoside antibiotics with standard care and the role of protective isolation in critically ill neutropenic patients with sepsis. Our goal is to see how these strategies impact survival and other health outcomes.

Healthy Participants>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Type 1 Diabetes: Low-Dose Interleukin-2 Study

We are studying the effects of low-dose interleukin-2 on patients with type 1 diabetes who still have some insulin production. The aim is to see if this treatment can help improve their immune response and insulin levels.

Type 1 DiabetesEfficacy phase (II)16-20 visitsInvestigational MedicinesEndocrinologyInternal Medicine

Lung Cancer Treatment: CT-P51 vs. Keytruda

We are comparing the effects and safety of CT-P51 and Keytruda in patients with untreated metastatic lung cancer. This study aims to find out if CT-P51 works as well as Keytruda when combined with chemotherapy.

Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Colorectal Cancer: New Immunotherapy Treatment

We are studying a combination of Pembrolizumab and a Dendritic Cell Vaccine, followed by other medications, for patients with advanced colorectal cancer that hasn't responded to prior treatments. The goal is to see if this approach improves survival and safety.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Asthma Treatment in Children: Salbutamol vs. Combination Therapy

We are studying whether using salbutamol alone is as effective as combining it with ipratropium bromide for treating moderate asthma attacks in children. This trial aims to find out which treatment helps reduce hospital admissions and improves recovery.

Acute Asthma Attack>2 yearsConfirmation phase (III)Investigational MedicinesPediatricsPulmonology